drugset / Trial / NCT01404013
Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma
Phase 4
Unknown
99 enrolled
The First Affiliated Hospital of Guangzhou Medical University
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to observe the therapeutic effect of leukotriene modulator montelukast alone or combined with inhaled corticosteroid(ICS) on cough variant asthma(CVA). The investigators hypothesize: 1. Cough score and cough reflex sensitivity will be improved after treatment with montelukast, inhaled corticosteroid/β2 agonist(ICS/LABA), and two combinations. 2. Combination of leukotriene modulator and inhaled corticosteroid/β2 agonist may have better efficacy when compared to montelukast, corticosteroid/β2 agonist alone while MON, is comparable to symbicort.
Timeline
- Start
- 2012-02
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Budesonide | Small molecule | 160 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 4.5 ug | Inhaled |
| Comparator | Montelukast | Other / unclassified | 10 mg | Oral |